Page last updated: 2024-11-04

rolipram and Obesity

rolipram has been researched along with Obesity in 5 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
" Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice."7.78Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. ( Ahmad, F; Baar, K; Beaven, MA; Brown, AL; Burgin, AB; Chung, JH; Ke, H; Kim, MK; Luo, H; Manganiello, V; Park, SJ; Philp, A; Rehmann, H; Taussig, R; Williams, T, 2012)
"Obesity is a major health problem."5.40The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity. ( Doseyici, S; Erbay, E; Mehmetoglu, I; Toker, A; Yerlikaya, FH, 2014)
" Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice."3.78Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. ( Ahmad, F; Baar, K; Beaven, MA; Brown, AL; Burgin, AB; Chung, JH; Ke, H; Kim, MK; Luo, H; Manganiello, V; Park, SJ; Philp, A; Rehmann, H; Taussig, R; Williams, T, 2012)
"Obesity is a major health problem."1.40The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity. ( Doseyici, S; Erbay, E; Mehmetoglu, I; Toker, A; Yerlikaya, FH, 2014)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Doseyici, S1
Mehmetoglu, I1
Toker, A1
Yerlikaya, FH1
Erbay, E1
Greene, M1
Thackeray, JT1
Kenk, M2
Thorn, SL1
Bevilacqua, L1
Harper, ME1
Beanlands, RS2
Dasilva, JN2
Thomas, A1
Lortie, M1
Dekemp, R1
Park, SJ1
Ahmad, F1
Philp, A1
Baar, K1
Williams, T1
Luo, H1
Ke, H1
Rehmann, H1
Taussig, R1
Brown, AL1
Kim, MK1
Beaven, MA1
Burgin, AB1
Manganiello, V1
Chung, JH1
Grønning, LM1
Baillie, GS1
Cederberg, A1
Lynch, MJ1
Houslay, MD1
Enerbäck, S1
Taskén, K1

Reviews

1 review available for rolipram and Obesity

ArticleYear
PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.
    Current radiopharmaceuticals, 2011, Volume: 4, Issue:1

    Topics: Animals; Asthma; Brain; Carbon Radioisotopes; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type

2011

Other Studies

4 other studies available for rolipram and Obesity

ArticleYear
The effects of forskolin and rolipram on cAMP, cGMP and free fatty acid levels in diet induced obesity.
    Biotechnic & histochemistry : official publication of the Biological Stain Commission, 2014, Volume: 89, Issue:5

    Topics: Animals; Colforsin; Cyclic AMP; Cyclic GMP; Diet, High-Fat; Fatty Acids, Nonesterified; Female; Lipo

2014
Reduced in vivo phosphodiesterase-4 response to acute noradrenaline challenge in diet-induced obese rats.
    Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:3

    Topics: Animals; Calorimetry, Indirect; Cyclic Nucleotide Phosphodiesterases, Type 4; Desipramine; Dietary F

2009
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.
    Cell, 2012, Feb-03, Volume: 148, Issue:3

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipose Tissue, White; Aging; AMP-Activated Protein Kinase Kina

2012
Reduced PDE4 expression and activity contributes to enhanced catecholamine-induced cAMP accumulation in adipocytes from FOXC2 transgenic mice.
    FEBS letters, 2006, Jul-24, Volume: 580, Issue:17

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipocytes; Adipose Tissue; Adrenergic beta-Agonists; Animals;

2006